Hemophilia is a group of hereditary bleeding disorders that result in severe coagulation disorders due to deficiencies of certain coagulation factors in the blood, and can occur in both men and women, but the majority of patients are male. These include hemophilia A (factor VIII, AHG deficiency), hemophilia B (factor IX deficiency, PTC deficiency), and hemophilia C (factor D, PTA deficiency). Hemophilia A is more common than hemophilia B, about seven times more common. Haemophilia mostly manifests as follows: 1. Skin and mucous membrane bleeding: the most common, occurring mostly after minor injuries, with persistent and continuous bleeding that can last for days or weeks, such as epistaxis and bleeding after tooth extraction. 2.Muscle bleeding: Subcutaneous and muscle bleeding, which can form hematomas. 3.Joint bleeding: A symptom specific to hemophilia, with an incidence of about 70~80% and rare in lighter patients. It mainly occurs in hemophilia A. 4, internal bleeding: hematuria, gastrointestinal bleeding is also more common. It is not terrible to have hemophilia. We now have recombinant human coagulation factor VIII and recombinant human coagulation factor IX, which can be applied regularly to many children to greatly reduce the chance of bleeding and the degree of bleeding, significantly improving the quality of life and reducing pain. Therefore, if you encounter a child who is prone to nosebleeds or soft tissue bleeding, be sure to check the blood routine and blood coagulation analysis to achieve early diagnosis and treatment. Since 2011, hemophilia has been included in the scope of medical insurance for rural children with major diseases. On January 1, 2015, the state re-adjusted the treatment policy and increased the annual compensation limit for patients with NNCC. In addition to the implementation of immediate outpatient settlement at designated hospitals, hemophilia patients who do not receive timely settlement for coagulation factor treatment at non-designated treatment hospitals or regular pharmacies (pharmaceutical companies) can present their drug receipts/invoices If a hemophiliac has not been reimbursed in time for coagulation factor treatment at a non-designated hospital or a regular pharmacy (pharmaceutical company), he/she can be reimbursed at the New Agricultural Cooperative Office in the region where he/she is located with the receipt/invoice of the medicine purchased and relevant medical records. This measure provides medical assistance to a greater extent for the children, relieves the financial burden of many families of the children, enables more children to receive timely and effective treatment, and saves the lives of many children.